These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 18521912

  • 1. Further experience with the use of 6-thioguanine in patients with Crohn's disease.
    Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J.
    Inflamm Bowel Dis; 2008 Oct; 14(10):1399-405. PubMed ID: 18521912
    [Abstract] [Full Text] [Related]

  • 2. Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study.
    Pavlidis P, Ansari A, Duley J, Oancea I, Florin T.
    Inflamm Bowel Dis; 2014 Dec; 20(12):2239-46. PubMed ID: 25230165
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
    Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A.
    BMC Gastroenterol; 2020 Sep 11; 20(1):296. PubMed ID: 32917155
    [Abstract] [Full Text] [Related]

  • 4. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, Peck-Radosavljevic M, Vogelsang H.
    Am J Gastroenterol; 2007 Nov 11; 102(11):2495-503. PubMed ID: 17894846
    [Abstract] [Full Text] [Related]

  • 5. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine.
    Seiderer J, Zech CJ, Reinisch W, Lukas M, Diebold J, Wrba F, Teml A, Chalupna P, Stritesky J, Schoenberg SO, Schima W, Göke B, Ochsenkühn T.
    J Hepatol; 2005 Aug 11; 43(2):303-9. PubMed ID: 15964660
    [Abstract] [Full Text] [Related]

  • 6. 6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.
    Almer SH, Hjortswang H, Hindorf U.
    Dig Liver Dis; 2009 Mar 11; 41(3):194-200. PubMed ID: 18799369
    [Abstract] [Full Text] [Related]

  • 7. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
    Gilissen LP, Derijks LJ, Driessen A, Bos LP, Hooymans PM, Stockbrügger RW, Engels LG.
    Dig Liver Dis; 2007 Feb 11; 39(2):156-9. PubMed ID: 17188950
    [Abstract] [Full Text] [Related]

  • 8. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
    van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI, Mulder CJ, van Nieuwkerk CM, Bloemena E, de Boer NK, van Bodegraven AA.
    Inflamm Bowel Dis; 2016 Sep 11; 22(9):2112-20. PubMed ID: 27482972
    [Abstract] [Full Text] [Related]

  • 9. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    van Asseldonk DP, Simsek M, de Boer NKH, Jharap B, Bloemena E, den Hartog G, Westerveld DB, Becx MC, Russel MG, Lissenberg-Witte BI, van Nieuwkerk CM, Mulder CJJ, Verheij J, van Bodegraven AA.
    Scand J Gastroenterol; 2019 Jun 11; 54(6):753-760. PubMed ID: 31203688
    [Abstract] [Full Text] [Related]

  • 10. Remission maintenance by tioguanine in chronic active Crohn's disease.
    Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF.
    Aliment Pharmacol Ther; 2003 Jun 15; 17(12):1459-64. PubMed ID: 12823147
    [Abstract] [Full Text] [Related]

  • 11. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF.
    Gastroenterology; 2003 Aug 15; 125(2):298-303. PubMed ID: 12891528
    [Abstract] [Full Text] [Related]

  • 12. Thioguanine in inflammatory bowel disease: Long-term efficacy and safety.
    Ward MG, Patel KV, Kariyawasam VC, Goel R, Warner B, Elliott TR, Blaker PA, Irving PM, Marinaki AM, Sanderson JD.
    United European Gastroenterol J; 2017 Jun 15; 5(4):563-570. PubMed ID: 28588888
    [Abstract] [Full Text] [Related]

  • 13. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
    Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W.
    Wien Klin Wochenschr; 2007 Jun 15; 119(17-18):519-26. PubMed ID: 17943403
    [Abstract] [Full Text] [Related]

  • 14. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease.
    Rulyak SJ, Saunders MD, Lee SD.
    J Clin Gastroenterol; 2003 Mar 15; 36(3):234-7. PubMed ID: 12590235
    [Abstract] [Full Text] [Related]

  • 15. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
    Musumba CO.
    Aliment Pharmacol Ther; 2013 Nov 15; 38(9):1025-37. PubMed ID: 24099468
    [Abstract] [Full Text] [Related]

  • 16. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
    Taylor KM, Ward MG, Blaker PA, Sparrow MP.
    Expert Rev Gastroenterol Hepatol; 2017 May 15; 11(5):473-486. PubMed ID: 28276819
    [Abstract] [Full Text] [Related]

  • 17. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease.
    Herrlinger KR, Fellermann K, Fischer C, Kreisel W, Deibert P, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Greinwald R, Stange EF, Schwab M.
    Aliment Pharmacol Ther; 2004 Jun 15; 19(12):1269-76. PubMed ID: 15191508
    [Abstract] [Full Text] [Related]

  • 18. The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.
    Crouwel F, Bayoumy AB, Mulder CJJ, Peters JHC, Boekema PJ, Derijks LJJ, de Boer SY, van de Meeberg PC, Ahmad I, Buiter HJC, de Boer NK.
    Inflamm Bowel Dis; 2024 Sep 03; 30(9):1492-1499. PubMed ID: 37658804
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease.
    Qasim A, McDonald S, Sebastian S, McLoughlin R, Buckley M, O'Connor H, O'Morain C.
    Scand J Gastroenterol; 2007 Feb 03; 42(2):194-9. PubMed ID: 17327939
    [Abstract] [Full Text] [Related]

  • 20. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.
    de Boer NK, Reinisch W, Teml A, van Bodegraven AA, Schwab M, Lukas M, Ochsenkühn T, Petritsch W, Knoflach P, Almer S, van der Merwe SW, Herrlinger KR, Seiderer J, Vogelsang H, Mulder CJ, Dutch 6-TG working group.
    Digestion; 2006 Feb 03; 73(1):25-31. PubMed ID: 16493198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.